Microneedle array patches (MAPs)
What are MAPs?
MAPs are a drug delivery platform enabling the delivery of drug or vaccine directly into the dermal layer of the skin, providing a potentially painless alternative to conventional injections.
Presenting as a patch for application to the skin, dissolvable microneedle patches release the active ingredient into the dermis following application. In an alternative presentation, coated microneedles contain the active ingredient within a coating. Hollow microneedles are a device through which active treatment is injected.
Figure 1. Microneedle array patch

Are there any approved MAP drug products on the market?
No, there are no approved MAP drug products available. The regulatory pathway for this new dosage form is being developed, paving the way for this novel delivery system as it advances through clinical studies.
A Phase 1/2 randomized controlled trial of a measles and rubella vaccine microneedle patch was conducted in 45 adults, 120 toddlers and 120 infants.1 This trial is an indication of the clinical feasibility and opportunity that this innovation presents. Microneedle products are being explored across a wide range of indications.
What are the value considerations for MAPs?
This alternative route of delivery presents a potential alternative to injectable products. Microneedles create an option for the delivery of molecules that are not structurally suited to development as an oral product or for sustained systemic exposure. MNAs are widely expected to deliver benefits associated with dose sparing, self-administration and patient adherence. MNAs address an unmet need for needle-phobic patients, particularly for paediatric patients. A further advantage for some microneedle products is thermostability – removing products from the requirement for cold storage. Phase 3 studies will reveal how these products are performing in terms of efficacy and safety. The localized delivery of medicines, in some cases avoiding systemic exposure, presents some opportunity in terms of differing safety profiles. There is interest in the clinical potential of achieving drug exposure at novel immunogenic sites within the skin or mucosa.
What are the payer value drivers for reimbursement of MAP products?
Early payer insights collected through a study conducted by Facilipharma indicate that payer priorities for favorable reimbursement will be relative clinical efficacy vs. current standard of care and the total treatment costs associated with MAP products. Self-administration was identified as an important perceived benefit of MAPs to payers overall. Payer insights acknowledged the benefits of thermostability from the global heath perspective e.g., in response to a pandemic, however this benefit may not be a driver for decision-making in markets without cold chain limitations.2 For an analogue product delivering self-administered influenza vaccine, the supporting evidence package included physician insights, a survey of adult patients, productivity insights and a human factors usability study.2
Early insights into microneedle products should be supplemented with detailed indication- and product- specific studies to establish target product profile, evidence requirements, and value strategy for market access and reimbursement.
Reference sources:
1. Adigweme, Ikechukwu et al. 2024 A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial; The Lancet, Volume 403, Issue 10439, 1879 – 18922. Chivers and Faisal, 2025. “Securing market access for MAPs” presented at Microneedle & Transdermal delivery forum 2025, Sept 9–10th 2025, Philadelphia, US
